Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.

MLA

Kim, Kwanghee, et al. “Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.” European Urology, vol. 87, no. 3, Mar. 2025, pp. 342–54. EBSCOhost, https://doi.org/10.1016/j.eururo.2024.10.024.

APA

Kim, K., Alam, S. M., Kuo, F., Chen, Z., Yip, W., Katims, A. B., Chu, C., Lenis, A. T., Hu, W., Gokturk Ozcan, G., Chen, J.-F., Firouzi, S., Elhanati, Y., Clinton, T. N., Aulitzky, A., Almassi, N., Fujii, Y., Tracey, A. T., Reisz, P. A., … Coleman, J. A. (2025). Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma. European Urology, 87(3), 342–354. https://doi.org/10.1016/j.eururo.2024.10.024

Chicago

Kim, Kwanghee, Syed M Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip, Andrew B Katims, Carissa Chu, et al. 2025. “Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma.” European Urology 87 (3): 342–54. doi:10.1016/j.eururo.2024.10.024.